FORMULATION ARTICLES
-
![GettyImages-1410189348]( "Nanosystems And Rare Diseases: Opportunities And Limitations")
Nanosystems And Rare Diseases: Opportunities And LimitationsNanosystems offer unique capabilities, enabling researchers to design precise, versatile delivery systems that address key challenges in rare diseases.
-
![cell biology, biochemistry, cellular signaling, cell integrity-GettyImages-2196575143]( "The Potency Chains Of Events For mRNA/LNP Therapeutics")
The Potency Chains Of Events For mRNA/LNP TherapeuticsPotency in mRNA/LNP therapies depends on two chains: manufacturing/cold chain integrity and complex in vivo delivery. Breakdowns at any step — from stability to translation — can limit efficacy and safety.
-
![Global health safety regulation-GettyImages-2245658628]( "How Informal FDA Feedback Is Quietly Driving RNA Capital Allocation")
How Informal FDA Feedback Is Quietly Driving RNA Capital AllocationSubtle FDA signals — especially in pre-IND talks — are quietly shaping RNA investment. Early regulatory feedback on CMC and comparability now drives how investors assess risk and allocate capital.
-
![Judges deck-pcr coronavirus-GettyImages-1285766387]( "From Pandemic Collaboration To Patent Litigation: BioNTech's Case Against Moderna")
From Pandemic Collaboration To Patent Litigation: BioNTech's Case Against ModernaBioNTech’s new lawsuit against Moderna highlights the intensifying post-COVID mRNA patent wars, as companies clash over vaccine design, delivery technologies, and the future of RNA therapeutics.
-
![compass on treasure map-GettyImages-157588143]( "Mapping The LNP Frontier: The Quest For Better LNPs")
Mapping The LNP Frontier: The Quest For Better LNPsHaving previously served as the head of delivery sciences for Moderna pre-pandemic, Almarsson was part of the RNA-LNP delivery journey long before it was scientifically en vogue. That’s why I was excited to sit down with him to discuss the latest and greatest advancements in the RNA-LNP space. Here, we take stock of the developments he’s been watching in the passive and active delivery spaces.
-
![Patent Wars-GettyImages-491938817]( "Inside The mRNA–LNP Patent Wars: A Q&A With Goodwin On Litigation, Strategy, And What Comes Next")
Inside The mRNA–LNP Patent Wars: A Q&A With Goodwin On Litigation, Strategy, And What Comes NextPatent disputes around mRNA constructs and LNP delivery are intensifying. Goodwin’s Natasha Daughtrey and Bill Christiansen unpack litigation trends, IP strategy, and what RNA developers should expect next.
FORMULATION VIDEOS
Dr. Gerrit Borchard, University of Geneva, presents a personal account of DNA vaccine development in a global pandemic.
In this segment, Replicate Biosciences’ Andy Geall, Qian Ruan, & Alex Aust identify the most promising technological and raw material innovations that are influencing the drug substance and drug product production processes at CDMOs.
Though there are a lot of exciting advancements being made with novel lipid chemistries, CMC Consultant Sujit Jain provides an important reality check for us: These innovations break established platforms, requiring fresh process development, complex impurity profiling, and new vendor qualifications.
A connected development pathway supports smoother scale-up and greater consistency for LNP-based therapeutics. Explore how integrated expertise across key stages helps teams accelerate progress.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1648451263 Scientist Holding Tray Of Medical Samples In Lab]( "Continuous Nanoparticle Manufacturing For Gene Editing Delivery")
Messenger RNA-LNPs are a promising strategy for delivering gene-editing components. Learn how a continuous manufacturing platform can address the scalability and reproducibility challenges of this process.
-
![Evonik1]( "How mRNA Technology Is Shaping The Future Of Medicine")
Discover how mRNA technologies open the doors to a whole range of new gene therapies and the role of lipid nanoparticles (LNPs) in current and future developments.
-
![GettyImages-1356994439-stem-cell-DNA-gene-editing-tweezers]( "Versatile Lipid Nanoparticle Platform For Efficient Gene Editing")
Lipid nanoparticles enable efficient gene editing in hard-to-transfect cells like T-cells and blood stem cells, which offers scalable, clinically relevant methods for developing advanced therapies for cancer and rare diseases.
-
![Science techonlogy-research-development-discovery-GettyImages-1209662272]( "Turbulent Mixing: Scaling Up Nanoparticle Manufacturing For The Future")
Choosing between turbulent and microfluidic mixing methods in your lipid nanoparticle (LNP) production can have a significant impact when scaling up production.
-
![GettyImages-1751659695-laboratory-scientists-computer-analysis-evaluation]( "CQA Assessment Of LNP-Encapsulated IVT mRNA")
Learn more about issued guidelines on Critical Quality Attributes for IVT mRNA vaccines and biotherapeutics to focus on drug substance and LNP-encapsulated drug product assessment using an analyzer system.
-
![mRNA GettyImages-1428646288]( "Early Spectroscopic Insights Into RNA Modifications In LNP Formulations With MMS")
Understand how Microfluidic Modulation Spectroscopy (MMS) provides early insights into RNA degradation within LNP formulations, offering a label-free approach to monitoring chemical integrity.
-
![GettyImages-1418152314]( "Unpacking The Importance Of Lipid Nanoparticle Production Platforms")
Batch processing platforms for LNPs lack efficiency, appropriate controls, and yield optimization. Continuous manufacturing platforms may address some of those issues.
